IMAGE Plus Consultants Limited (IPCL), a Jamaica-based diagnostic imaging firm listed on the Junior Market, has announced a transformative double strategic move: it will acquire the only private MRI and bone densitometry provider in central Jamaica while absorbing its largest competitor on the country’s north coast. The deal marks the company’s bet that this industry consolidation will finally convert years of heavy capital investment into meaningful bottom-line growth after a prolonged period of stalled revenue expansion.
Under the terms of the agreement, IPCL will take ownership of all assets and the established brand of Island Radiology, which currently operates full branches in Mandeville and Ocho Rios, plus an underutilized agency outlet in Santa Cruz. Once finalized, the transaction will grant Image Plus an exclusive private hold on high-margin diagnostic imaging services across central Jamaica, while bringing the entire existing patient base of its top Ocho Rios competitor into the IPCL network. The acquisition price has not been publicly disclosed, with CEO Kisha Anderson confirming that full financial breakdowns will be released at the company’s upcoming annual general meeting, scheduled to take place on July 14. This deal was first teased in July 2025, coming months before IPCL completed its November 2025 purchase of women’s health provider The Woman’s Place.
The push for consolidation comes against a backdrop of underwhelming financial performance, even as IPCL has poured hundreds of millions into expanding capacity and capabilities. Audited results for the 12-month period ending February 2026 show only marginal top-line growth: total inched revenue up to JMD $1.092 billion, from $1.081 billion the prior year. Operating profit slipped slightly to $77.2 million from $79.8 million, though net profit did see a small uptick to $48.7 million, up from $43.9 million a year earlier.
In an interview with the Jamaica Observer on Thursday, Anderson acknowledged the company’s slow growth trajectory, admitting, “Growth levels have been modest, more flat, if I’m going to be a little bit more accurate.”
The audited financial statements released Wednesday outline two overlapping challenges that held back performance over the past year. The first was extreme weather disruption: Hurricane Melissa caused roughly three weeks of reduced patient volumes at IPCL’s Ocho Rios location, not due to infrastructure damage or power loss at the facility itself, but because widespread community dislocation left local patients unable to travel to keep scheduled appointments. Anderson noted, “We powered the location in St Ann by generator even when the rest of the parish was down,” underscoring that the disruption stemmed from broader community impact rather than operational failure at the clinic.
The second, more structural challenge came from a shift in government health policy. Jamaica’s Ministry of Health cut subsidy rates for patients accessing diagnostic services at private providers, which shrank the steady stream of government-linked referrals that had long supported IPCL’s revenue base. The company has had to pivot to attracting more self-paying patients to offset the lost volume from the policy change.
This strategic shift is clearly reflected in the company’s balance sheet: trade and other receivables dropped sharply to $150.7 million from $369.8 million year-over-year, a change that reflects both reduced exposure to delayed government payments and improved collection rates from private paying patients. Even so, the policy shift has forced the company to focus on stabilizing revenue rather than pursuing growth, while rising costs have continued to pressure margins. Administrative expenses climbed to $520.8 million, depreciation hit $114.3 million, and finance costs remained elevated at $38.5 million over the reporting period.
Over the past year, IPCL has also maintained aggressive capital investment: the company spent $132.8 million on new diagnostic equipment and an additional $52.4 million on prior acquisitions. These outlays have expanded the company’s overall capacity, but have yet to generate a corresponding lift in earnings. The end result is a business that has expanded its geographic footprint and service offerings, but has failed to deliver the profit growth that investors have been waiting for.
Anderson and the IPCL leadership team believe the Island Radiology acquisition will reverse this trajectory. The CEO projects that the company will see a measurable lift in both revenue and net profit by the third quarter of the current financial year, as the newly acquired operations are integrated and patient volumes build across the combined network. She added that debt servicing for the acquisition is already covered by Island Radiology’s existing patient volume, even before factoring in planned growth, and that combined operational scale will improve IPCL’s purchasing power with suppliers, creating additional room for margin expansion beyond the base case. Anderson explained, “With Island Radiology… we’ll be able to open for longer hours and… take more capacity in terms of patient appointments.”
A key advantage of the deal is the ability to leverage IPCL’s existing team of more than 20 radiologists across the acquired locations. This additional staffing will allow the combined network to extend operating hours and handle a higher daily volume of cases than Island Radiology could support with its smaller, under-resourced team.
The consolidation is particularly impactful in Ocho Rios, where IPCL will operate two complementary locations once the deal closes. Anderson noted, “In Ocho Rios, Island would have been our largest competitor… we now are able to consolidate.” She added that the acquired Island Radiology facility at Eight Rivers, located near central Ocho Rios, draws patients from a different geographic catchment area than IPCL’s existing White River North clinic, creating minimal overlap and maximum incremental volume.
Outside of Ocho Rios, IPCL plans to reactivate the dormant Santa Cruz agency, which Island Radiology was unable to operate consistently due to a shortage of radiologists. Anderson projects the site will reopen around June, once additional staffing is deployed, and will serve patients across St Elizabeth parish extending all the way to the Westmoreland border. “We’re going to have the capacity… to have more throughput per day,” she said.
The acquisition will be initially funded through new borrowings, but Anderson argues that the deal is structured to be self-sustaining, with no drag on existing IPCL profit levels. “We’re going to initially fund it in debt… the acquisition can pay for itself… so that there’s no pull on our existing profit levels,” she said, noting that the operational improvements IPCL will bring to the combined network will generate enough additional cash flow to service the debt.
Anderson acknowledged that the deal carries some risk, noting, “The biggest risk could be that we don’t manage a transition well… or any disruption to relationships… or any unforeseen breakdown in equipment.” To mitigate these risks, IPCL plans to retain core parts of Island Radiology’s existing operation, including key medical staff and elements of the established brand, while folding back-office and administrative functions into the larger IPCL group to cut redundant costs.
Following the close of the Island Radiology deal, Anderson confirmed that IPCL’s acquisition spree will come to an end. With The Woman’s Place acquisition completed in November 2025 and the Island Radiology deal agreed in principle (pending finalization of a definitive sale and purchase agreement), the company’s top priority will now shift to integrating existing assets and unlocking value from the expanded footprint. “We don’t plan on acquiring anything else right now… what we’re going to do now is just extract value,” she told BusinessWeek.
To date, IPCL has expanded its geographic reach, absorbed its largest north coast competitor, and secured exclusive private MRI capability in central Jamaica, but its financial results make clear that scale alone has not delivered stronger earnings. The company is now betting that increased patient volume and operational efficiencies will close the gap between its expanded footprint and profit growth, with the third quarter of the current fiscal year marked as the first milestone to prove the strategy works. Markets reacted positively to the acquisition announcement on Thursday: IPCL shares closed trading at $0.90, up $0.16, a gain of 21.62 percent. The company listed on the Junior Market in January 2023 at an initial price of $2.00 per share. Anderson argued that the market has yet to price in the full value of the company’s transformed position, saying, “I don’t think the share price reflects the value of the entity.”